AR104805A1 - METHODS AND COMPOSITIONS TO EVALUATE CANCER RESPONSE RESPONSE TO BET INHIBITORS - Google Patents
METHODS AND COMPOSITIONS TO EVALUATE CANCER RESPONSE RESPONSE TO BET INHIBITORSInfo
- Publication number
- AR104805A1 AR104805A1 ARP160101552A ARP160101552A AR104805A1 AR 104805 A1 AR104805 A1 AR 104805A1 AR P160101552 A ARP160101552 A AR P160101552A AR P160101552 A ARP160101552 A AR P160101552A AR 104805 A1 AR104805 A1 AR 104805A1
- Authority
- AR
- Argentina
- Prior art keywords
- methods
- cancer
- response
- subject
- bet
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se describen métodos de tratamiento de un sujeto que tiene cáncer con un inhibidor de BET, métodos de selección de un sujeto para el tratamiento con un inhibidor de BET, métodos de predicción de la capacidad de respuesta de un sujeto que tiene cáncer a un inhibidor de BET, métodos de comunicación de la probabilidad de respuesta de un sujeto que tiene cáncer a un inhibidor de BET y métodos de modulación del tratamiento de un sujeto que se somete a un tratamiento con inhibidores de BET para cáncer. Los métodos descritos incluyen las etapas para llevar a cabo un ensayo de detección a base de ácido nucleico para detectar el nivel de expresión de un eARN transcrito de un elemento potenciador asociado con mic en una muestra que contiene células cancerosas del sujeto y determinar el nivel de expresión del eARN en las células en la muestra.Methods of treating a subject who has cancer with a BET inhibitor, methods of selecting a subject for treatment with a BET inhibitor, methods of predicting the responsiveness of a subject having cancer to an inhibitor of cancer are described. BET, methods of communicating the likelihood of response of a subject who has cancer to a BET inhibitor and methods of modulating the treatment of a subject undergoing treatment with BET inhibitors for cancer. The methods described include the steps to carry out a nucleic acid based detection assay to detect the level of expression of a transcribed eRNA of an enhancer element associated with mic in a sample containing the subject's cancer cells and determine the level of eRNA expression in the cells in the sample.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562168691P | 2015-05-29 | 2015-05-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR104805A1 true AR104805A1 (en) | 2017-08-16 |
Family
ID=56117996
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP160101552A AR104805A1 (en) | 2015-05-29 | 2016-05-27 | METHODS AND COMPOSITIONS TO EVALUATE CANCER RESPONSE RESPONSE TO BET INHIBITORS |
Country Status (2)
Country | Link |
---|---|
AR (1) | AR104805A1 (en) |
WO (1) | WO2016196065A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11708600B2 (en) * | 2017-10-05 | 2023-07-25 | Decode Health, Inc. | Long non-coding RNA gene expression signatures in disease diagnosis |
WO2019113260A1 (en) * | 2017-12-05 | 2019-06-13 | The Regents Of The University Of Colorado A Body Corporate | Genomic targets of histone deacetylase inhibitors (hdaci) and methods of use thereof |
WO2020227213A1 (en) * | 2019-05-03 | 2020-11-12 | Icahn School Of Medicine At Mount Sinai | Methods of controlling and improving brain health |
CN115190800A (en) * | 2020-03-09 | 2022-10-14 | 石药集团中奇制药技术(石家庄)有限公司 | Application of BRD4 inhibitor |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
DE69717160T2 (en) | 1996-09-13 | 2003-05-08 | Mitsubishi Pharma Corp., Osaka | THIENOTRIAZOLODIAZEPINE COMPOUNDS AND THEIR MEDICAL APPLICATIONS |
EP1276702A2 (en) | 2000-03-31 | 2003-01-22 | Genentech, Inc. | Compositions and methods for detecting and quantifying gene expression |
WO2006129623A1 (en) | 2005-05-30 | 2006-12-07 | Mitsubishi Tanabe Pharma Corporation | Thienotriazolodiazepine compound and a medicinal use thereof |
MX2009008099A (en) | 2007-02-01 | 2009-12-14 | Resverlogix Corp | Compounds for the prevention and treatment of cardiovascular diseases. |
JP5478262B2 (en) | 2007-12-28 | 2014-04-23 | 田辺三菱製薬株式会社 | Anticancer drug |
SI2346837T1 (en) | 2008-06-26 | 2015-05-29 | Resverlogix Corporation | Methods of preparing quinazolinone derivatives |
PL2421533T3 (en) | 2009-04-22 | 2019-05-31 | Resverlogix Corp | Novel anti-inflammatory agents |
GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
GB0919426D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
EP2496582B1 (en) | 2009-11-05 | 2016-01-27 | GlaxoSmithKline LLC | Benzodiazepine bromodomain inhibitor |
GB0919432D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
CN103154246B (en) | 2010-05-14 | 2015-11-25 | 达那-法伯癌症研究所 | Be used for the treatment of leukemic composition and method |
JP5913292B2 (en) | 2010-05-14 | 2016-04-27 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | Compositions and methods for modulating metabolism |
CN104311562B (en) | 2010-05-14 | 2017-07-04 | 达那-法伯癌症研究所 | For treating neoplasia, inflammatory disease and the composition and method of other imbalances |
JP5844358B2 (en) | 2010-06-22 | 2016-01-13 | グラクソスミスクライン エルエルシー | Bromodomain inhibitors containing benzotriazolodiazepine compounds |
AR084070A1 (en) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | BROMODOMINIUM INHIBITORS AND USES OF THE SAME |
WO2012116170A1 (en) | 2011-02-23 | 2012-08-30 | Ming-Ming Zhou | Inhibitors of bromodomains as modulators of gene expression |
EP2705039B1 (en) | 2011-05-04 | 2017-07-26 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
WO2012174487A2 (en) | 2011-06-17 | 2012-12-20 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
GB201114103D0 (en) | 2011-08-17 | 2011-09-28 | Glaxosmithkline Llc | Novel compounds |
WO2013027168A1 (en) | 2011-08-22 | 2013-02-28 | Pfizer Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
WO2013033270A2 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bromodomain ligands capable of dimerizing in an aqueous solution, and methods of using same |
WO2013033420A1 (en) * | 2011-08-30 | 2013-03-07 | Whitehead Institute For Biomedical Research | Methods of downregulating translocated oncogene expression using bromodomain inhibitors |
DE102011082013A1 (en) | 2011-09-01 | 2013-03-07 | Bayer Pharma AG | 6H-thieno [3,2-f] [1,2,4] triazolo [4,3-a] [1,4] diazepines |
WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
US9763956B2 (en) * | 2012-06-19 | 2017-09-19 | The Broad Institute, Inc. | Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy |
-
2016
- 2016-05-23 WO PCT/US2016/033826 patent/WO2016196065A1/en active Application Filing
- 2016-05-27 AR ARP160101552A patent/AR104805A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2016196065A1 (en) | 2016-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201991105A1 (en) | RISK ASSESSMENT METHODS USING TOTAL AND SPECIFIC NON-CELLULAR DNA | |
AR102518A1 (en) | METHODS AND BIOMARKERS TO PREACH THE EFFECTIVENESS AND EVALUATION OF AN OX40 AGONIST TREATMENT | |
MX2017003790A (en) | Target sequence detection by nanopore sensing of synthetic probes. | |
BR112018069849A2 (en) | kit, device and method for the detection of early pancreatic cancer or pancreatic cancer precursor lesion | |
MX2022007933A (en) | Polymethine compounds and their use as fluorescent labels. | |
BR112017007965A2 (en) | computer-implemented method for inferring the activity of a tgf-b cell signaling pathway in an individual; apparatus for inferring the activity of a tgf-b cellular signaling pathway in an individual; non-transient storage medium; computer program; kits for measuring expression levels of three or more tgf-b cell signaling pathway target genes in a sample from an individual; infer the activity of a tgf-b cell signaling pathway in an individual; infer the activity of a tgf-b cell signaling pathway in an individual; and use of the kit | |
EA201891304A1 (en) | MAT2A INHIBITORS FOR THE TREATMENT OF MTAP-null MALIGNANT TUMORS | |
BR112016008970A2 (en) | EX VIVO ACTIVATION METHOD AND TO EVALUATE PLASMA ACTIVATION IN AN INDIVIDUAL, EX VIVO ASSAY TO DETERMINE PLASMA KALLICREIN ACTIVITY IN A SAMPLE | |
MX2017010836A (en) | Biomarker panel for the detection of cancer. | |
EA201692157A1 (en) | SYNTHESIS OF TWO-CELLULAR NUCLEIC ACIDS | |
PH12017501967A1 (en) | Maize plant dbn9936 and method for use in detecting nucleic acid sequence thereof | |
AR104805A1 (en) | METHODS AND COMPOSITIONS TO EVALUATE CANCER RESPONSE RESPONSE TO BET INHIBITORS | |
SA518392005B1 (en) | Deep sequencing profiling of tumors | |
EA201790769A1 (en) | DETERMINATION OF THE LEVELS OF GLYCOSAMINOGLICANES BY THE MASS SPECTROMETRY METHOD | |
CL2017001487A1 (en) | Use of fgfr bread inhibitors and method for identification of cancer patients eligible for treatment with an fgfr bread inhibitor. | |
CL2017001929A1 (en) | Method and product | |
MX2024003382A (en) | Compositions and methods for detecting circulating tumor dna. | |
BR112017023473A2 (en) | nucleic acid detection and quantification method and compositions | |
EA201891478A1 (en) | METHODS AND COMPOSITIONS FOR RISK ASSESSMENT FOR CANCER | |
GB2542576A (en) | Method and kit of detecting the absence of micro-oranisms | |
PH12015501778A1 (en) | Markers associated with wnt inhibitors | |
CL2020002715A1 (en) | Compositions and methods for treating endometriosis | |
BR112016015537A2 (en) | methods and kits for detecting the presence of the polynucleotide sequence of e.g. histolytica in sample | |
BR112016004450A2 (en) | methods for treating a disease, for increasing the effectiveness of a treatment, for postponing and / or preventing the development of recurrence and / or resistance of a disease, for increasing sensitivity to an inhibitor, for extending the sensitivity period for an inhibitor and for extend response time to an inhibitor | |
CL2016003162A1 (en) | Prediction of the ability of Atlantic salmon to use dietary pigment based on the determination of polymorphisms. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |